Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results